700 patients110,866 observations180 daysLIVE

Patient P-02433

Synthetic patientMETA-24 · Day 164 · 25–34 · M · baseline S07Steering view · 3DOpen companion preview
Therapy response
Favorable
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
65%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S07
  2. Day 122 GI-04 recommendedGI Support Protocol GI-04
  3. Day 123 Patient acceptedStarted GI-04 in the companion
  4. Day 131 GI symptom burden −23% vs expectedGI Support Protocol GI-04
  5. Day 135 Trajectory diverged from predictionObserved response fell below the model's expected path.
  6. Day 137 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 135.

Primary contributors, last 14 days
  • Nutritional resilience-16
  • GI instability+13
  • Treatment adherence-12
  • Inflammatory activity-3

What helped?

  • GI Support Protocol GI-04Day 122
    Result: symptom burden −23%
LIFE OS recommendation
Monitoring Escalation ME-01
77%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 100% showed improvement
  • median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes
Wearable
25 min
improving · +7.2 vs previous 14 d
Sleep duration
Wearable
6.3 h
stable · -0.2 vs previous 14 d
Energy level
Daily log
2.9/10
stable · -0.0 vs previous 14 d
Steps
Wearable
1,885
improving · +410 vs previous 14 d
GI burden
Companion
51.4/100
stable · +0.1 vs previous 14 d
Adherence
Companion
66.7 %
worsening · -11.3 vs previous 14 d
Sleep quality
Wearable
21.8/100
stable · +0.5 vs previous 14 d
Glucose, CGM daily mean
CGM
148 mg/dL
stable · +1.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 46 from the failing basin, 45 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 41 similar · onset 3 d · confidence 65%
  • NP-02 Dietary Support Protocol
    59% improved among 32 similar · onset 10 d · confidence 65%
  • SC-12 Supportive Compound
    69% improved among 26 similar · onset 6 d · confidence 65%
  • More protein
    GI -5.1 next day on high-intake days · n 17
Would not help
  • Keep fat low
    GI +4.8 next day on high-intake days · n 21
  • Keep histamine low
    GI +3.2 next day on high-intake days · n 23
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -5.1supporter · 95%
  • Dietary fat load
    +4.8detractor · 95%
  • Histamine load
    +3.2detractor · 95%
  • Caffeine
    +1.4no signal · 40%
  • Alcohol
    +0.6no signal · 15%
  • Simple carbohydrates
    -0.5no signal · 16%
  • Ultra-processed food
    -0.1no signal · 15%
  • Insoluble fibre
    0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 51 and rising
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 39/100
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 40
    • BloodInflammatory load index 46
    • WearableHRV 17 ms, trending down
  • Autonomic recovery 40
    • Wearable1,885 steps/day
    • WearableShort sleep window
  • Drug metabolism and exposure 20
    • BloodToxicity index 43
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 39/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisNormal
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
25 ms
Sleep
6.6 h
Steps
2,118
Resting HR
69 bpm
Daily log: GI score 51, nutritional resilience 39, adherence 67.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0248326%S06BR-03no change64
P-0205441%S01CR-01improved57
P-0215138%S04CR-01improved49
P-0223337%S16CR-01improved66
P-0200936%S08CR-01improved64
P-0202533%S15CR-01improved61
P-0215432%S16CR-01improved57
P-0235424%S01CR-01improved78
P-0249126%S09DT-01no change65
P-0227424%S15DT-01improved50
P-0233924%S03DT-01improved50
P-0239524%S12DT-01improved57